Bispecific Antibody Market Expected to Reach $109.4 Billion by 2032

Bispecific antibodies are artificial proteins that have promising applications in the field of cancer and immunotherapy. They are comprised of two monoclonal antibodies which are held together by a flexible peptide linker. This makes them able to bind to two different antigens, as the name suggests. The unique properties of bispecific antibodies make them versatile therapeutic agents. They improve therapy effectiveness, target certain cell types, and address complex disease pathways. Bispecific antibodies act as a bridge between cancer cells and cytotoxic T lymphocytes (CTLs). They bind CD3 antigens on CTLs and a specific antigen on cancer cells, which in turn activates the T cells, promotes the lysis of cancer cells, and make bispecific antibody effective in cancer treatment.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
Regeneron Pharmaceuticals, Inc., Johnson & Johnson, MacroGenics Inc., Bristol-Myers Squibb Company, AbbVie Inc, Amgen Inc., Pfizer Ltd, F. Hoffmann-La Roche Ltd., Merus, AstraZeneca plc

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/130431

On the basis of product, the bispecific antibody market size is classified into blinatumomab, emicizumab, and others. Others includes elranatamab, mosunetuzumab, glofitamab, and zenocutuzumab. The blinatumomab segment is expected to be the fastest-growing segment during the forecast period owing to the increase in incidences of leukemia and rise in technological advances in the field of cancer treatments.

On the basis of application, the bispecific antibody market analysis is classified into cancer, hemophilia, and others. Others includes autoimmune diseases, neovascular age-related macular degeneration, and Alzheimer disease. The hemophilia segment is projected to be the fastest growing segment during the forecast period, owing to a rise in the number of populations suffering from hemophilia and increase in the awareness among the people regarding treatment of hemophilia.

On the basis of end user, the bispecific antibody market share is classified into hospitals, cancer centers, and others. The hospitals segment is projected to be the fastest growing segment during the forecast period owing to rise in the number of initiatives taken by government for development of healthcare infrastructure and rise in the prevalence of chronic diseases and autoimmune diseases.

On the basis of region, North America had the highest bispecific antibody market share in 2022 and is expected to maintain its lead during the forecast period owing to increase in prevalence of cancer, growth in demand for next-generation antibody therapeutics, and technological advancement in the healthcare sector. However, Asia-Pacific is expected to exhibit the fastest growth during the forecast period, owing to the fact that this region has large and growing population, which is susceptible to the rise in prevalence of infectious diseases, rise in the number of product approvals for bispecific antibodies and increase in the strategic partnership among the market players.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/130431

𝐎𝐮𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐏𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐘𝐨𝐮 𝐀𝐧𝐬𝐰𝐞𝐫 𝐭𝐨 𝐁𝐞𝐥𝐨𝐰 𝐌𝐞𝐧𝐭𝐢𝐨𝐧𝐞𝐝 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧:

• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2023?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.